Home » Stocks » IPA

ImmunoPrecise Antibodies Ltd. (IPA)

Stock Price: $15.75 USD -0.30 (-1.87%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 248.11M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 15.65M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $15.75
Previous Close $16.05
Change ($) -0.30
Change (%) -1.87%
Day's Open 15.80
Day's Range 14.85 - 15.80
Day's Volume 54,897
52-Week Range 13.40 - 16.73

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody...

Business Wire - 2 weeks ago

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, today ...

Business Wire - 3 weeks ago

VICTORIA, British Columbia--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. ("Company" or "IPA") (TSXV: IPA) (Nasdaq: IPA), a leader in full-service, therapeutic antibody discovery and developm...

PRNewsWire - 2 months ago

VICTORIA, BC, Nov. 3, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discover...

Bloomberg Technology - 3 months ago

Developing Antibodies for Covid-19

Sep.28 -- Jennifer Bath, chief executive officer at Immunoprecise Antibodies Ltd., discusses the company's potentially groundbreaking Covid-19 antibody treatment on "Bloomberg Technology.

About IPA

ImmunoPrecise Antibodies engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; t... [Read more...]

Industry
Biotechnology
IPO Date
Jan 3, 2017
Stock Exchange
NASDAQ
Ticker Symbol
IPA
Full Company Profile

Financial Performance

In 2020, IPA's revenue was 14.06 million, an increase of 28.66% compared to the previous year's 10.93 million. Losses were -4.95 million, -35.05% less than in 2019.

Financial numbers in millions CAD.
Financial Statements